Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Nature Medicine

Volumn 24, Issue 5, 2018, Pages 563-571

  Fraietta, Joseph A ^a,b   Lacey, Simon F ^a,b   Orlando, Elena J ^c   Pruteanu Malinici, Iulian ^c   Gohil, Mercy ^b   Lundh, Stefan ^b   Boesteanu, Alina C ^b   Wang, Yan ^b   O'connor, Roddy S ^b   Hwang, Wei Ting ^a   Pequignot, Edward ^b   Ambrose, David E ^b   Zhang, Changfeng ^b   Wilcox, Nicholas ^b   Bedoya, Felipe ^b   Dorfmeier, Corin ^b   Chen, Fang ^b   Tian, Lifeng ^b   Parakandi, Harit ^b   Gupta, Minnal ^b   Young, Regina M ^b   Johnson, F Brad ^a   Kulikovskaya, Irina ^b   Liu, Li ^b   Xu, Jun ^b   Kassim, Sadik H ^c   Davis, Megan M ^a,b   Levine, Bruce L ^a,b   Frey, Noelle V ^a,b   Siegel, Donald L ^a,b   Huang, Alexander C ^a,b   Wherry, E John ^a,b   Bitter, Hans ^c   Brogdon, Jennifer L ^c   Porter, David L ^a   June, Carl H ^a,b   Melenhorst, J Joseph ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL RECEPTOR; CD27 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 6; STAT3 PROTEIN; CD19 ANTIGEN; INTERLEUKIN 6 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; TISAGENLECLEUCEL T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA REMISSION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUMOR REJECTION; AEROBIC GLYCOLYSIS; APOPTOSIS; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN CELL; LETTER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ENGRAFTMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GENETIC TRANSCRIPTION; IMMUNOLOGY; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD19; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-6; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; RECEPTORS, CHIMERIC ANTIGEN; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 85046093409     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0010-1     Document Type: Article

References (55)

1. Makkouk, A. & Weiner, G. J. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 75, 5-10 (2015).
2. Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
3. Brown, J. R. et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123, 3390-3397 (2014).
4. Jain, P. et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125, 2062-2067 (2015).
5. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
6. Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
7. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
8. + CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).
9. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
10. + composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123-2138 (2016).
11. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
12. Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 712 (2016).
13. + T cells. J. Clin. Invest. 115, 1616-1626 (2005).
14. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106, 17469-17474 (2009).
15. Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297 (2011).
16. Radvanyi, L. G. et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758-6770 (2012).
17. Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557 (2011).
18. + T cell differentiation. Immunity 33, 128-140 (2010).
19. Betz, U. A. & Müller, W. Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation. Int. Immunol. 10, 1175-1184 (1998).
20. Siegel, A. M. et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35, 806-818 (2011).
21. Lugli, E. et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat. Protoc. 8, 33-42 (2013).
22. Bruggner, R. V., Bodenmiller, B., Dill, D. L., Tibshirani, R. J. & Nolan, G. P. Automated identification of stratifying signatures in cellular subpopulations. Proc. Natl. Acad. Sci. USA 111, E2770-E2777 (2014).
23. Aghaeepour, N. et al. Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics 28, 1009-1016 (2012).
24. + phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. Blood 113, 3209-3217 (2009).
25. + T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 100, 933-940 (2002).
26. + T subsets with distinct replicative history and partial effector functions. Blood 102, 1779-1787 (2003).
27. + T cell responses. J. Exp. Med. 204, 1405-1416 (2007).
28. + selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. J. Immunother. Cancer 5, 14 (2017).
29. Jones, R. B. et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205, 2763-2779 (2008).
30. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
31. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
32. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537-1544 (2009).
33. + T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175-2186 (2010).
34. + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117, 3383-3392 (2007).
35. Grosso, J. F. et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182, 6659-6669 (2009).
36. Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464 (2009).
37. + -selected hematopoietic cell transplantation. Blood 102, 2004-2013 (2003).
38. Ruella, M. et al. The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin. Cancer Res. 22, 2684-2696 (2016).
39. Fraietta, J. A. et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117-1127 (2016).
40. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
41. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
42. Anders, S., Pyl, P. T. & Huber, W. HTSeq: a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015).
43. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
44. Luckey, C. J. et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 103, 3304-3309 (2006).
45. McKinney, E. F., Lee, J. C., Jayne, D. R., Lyons, P. A. & Smith, K. G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612-616 (2015).
46. + T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
47. Abbas, A. R. et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6, 319-331 (2005).
48. + memory T cells are preferential targets for bystander activation and apoptosis. J. Immunol. 182, 1962-1971 (2009).
49. Ramirez, K. et al. Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. Immunity 36, 921-932 (2012).
50. Winter, S. C. et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 67, 3441-3449 (2007).
51. Campia, I. et al. An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells. PLoS One 10, e0126159 (2015).
52. Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8, e57838 (2013).
53. Cawthon, R. M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 30, e47 (2002).
54. Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994).
55. Herbert, B. S., Hochreiter, A. E., Wright, W. E. & Shay, J. W. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat. Protoc. 1, 1583-1590 (2006).